Latest news with #Cannabis
Yahoo
3 days ago
- Business
- Yahoo
Tilray (TLRY) Reports Q2: Everything You Need To Know Ahead Of Earnings
Cannabis company Tilray Brands (NASDAQ:TLRY) will be announcing earnings results this Monday afternoon. Here's what you need to know. Tilray missed analysts' revenue expectations by 10.1% last quarter, reporting revenues of $185.8 million, down 1.4% year on year. It was a slower quarter for the company, with a significant miss of analysts' EBITDA estimates and a significant miss of analysts' gross margin estimates. Is Tilray a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Tilray's revenue to be flat year on year at $229.2 million, slowing from the 24.8% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tilray has missed Wall Street's revenue estimates four times over the last two years. Looking at Tilray's peers in the beverages, alcohol, and tobacco segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Beer delivered year-on-year revenue growth of 1.5%, meeting analysts' expectations, and Coca-Cola reported revenues up 2.1%, topping estimates by 0.5%. Boston Beer traded up 6.5% following the results while Coca-Cola was down 1.4%. Read our full analysis of Boston Beer's results here and Coca-Cola's results here. There has been positive sentiment among investors in the beverages, alcohol, and tobacco segment, with share prices up 5.5% on average over the last month. Tilray is up 72.5% during the same time and is heading into earnings with an average analyst price target of $1.04 (compared to the current share price of $0.69). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Sign in to access your portfolio
Yahoo
3 days ago
- Business
- Yahoo
Tilray (TLRY) Reports Q2: Everything You Need To Know Ahead Of Earnings
Cannabis company Tilray Brands (NASDAQ:TLRY) will be announcing earnings results this Monday afternoon. Here's what you need to know. Tilray missed analysts' revenue expectations by 10.1% last quarter, reporting revenues of $185.8 million, down 1.4% year on year. It was a slower quarter for the company, with a significant miss of analysts' EBITDA estimates and a significant miss of analysts' gross margin estimates. Is Tilray a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Tilray's revenue to be flat year on year at $229.2 million, slowing from the 24.8% increase it recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Tilray has missed Wall Street's revenue estimates four times over the last two years. Looking at Tilray's peers in the beverages, alcohol, and tobacco segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Boston Beer delivered year-on-year revenue growth of 1.5%, meeting analysts' expectations, and Coca-Cola reported revenues up 2.1%, topping estimates by 0.5%. Boston Beer traded up 6.5% following the results while Coca-Cola was down 1.4%. Read our full analysis of Boston Beer's results here and Coca-Cola's results here. There has been positive sentiment among investors in the beverages, alcohol, and tobacco segment, with share prices up 5.5% on average over the last month. Tilray is up 72.5% during the same time and is heading into earnings with an average analyst price target of $1.04 (compared to the current share price of $0.69). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CBC
6 days ago
- CBC
Canada Border Services Agency intercepting more cannabis at Calgary International Airport
Cannabis may be legal in Canada, but there's still an illegal market overseas. Over the past year the CBSA has seized more than 160 kilograms of cannabis at the Calgary International Airport, much of it destined for the United Kingdom.
News.com.au
22-07-2025
- Business
- News.com.au
Biocurious: The cannabis stocks that stand out in a field of weeds
Cannabis suppliers are struggling to differentiate themselves in a commoditised market Regulators have lax telehealth prescribers in their sights Althea Group has sold its medical pot arm in favour of THC-infused beverages Having sprouted in a field of hope and hype eleven years ago, the ASX medicinal cannabis sector has wilted in the face of unrealistic expectations and misguided strategies. Demand isn't the problem: patients have embraced medical weed zealously since it was legalised a decade ago. Globally, most western countries have sanctioned both medical usage and many have condoned recreational indulgence (including most US states). Because there's only two approved cannabis treatments, local dispensing is largely carried out via an authorised prescriber scheme. In the six months to December 2024, these docs wrote 377,840 prescriptions. Of these, 230,091 were for products with a THC content of more than 98%. Patients aren't mucking around. What's not to like? The answer is rampant oversupply of the green stuff coupled with the rise of telehealth clinics, some of which are being criticised for alleged 'tick and flick' dispensing practices. Echoing Australian Medical Association concerns, Little Green Pharma (ASX:LGP) CEO Paul Long refers to 'poor actors' in the local market. 'Reports constantly refer to a handful of doctors, often junior doctors that are either being coerced, or paid exorbitant money to write a huge volume of THC scripts,' he says. 'I agree it is an issue and calling it out for the long-term growth of our industry is important." He adds hundreds of thousands have tried medical cannabis when nothing has worked, with great success. Reflecting the 'commoditised' market, Althea Group (ASX:AGH) in May sold its local medical cannabis business, Tasmanian Botanics Pty Ltd for a knock-down $1 million. 'The market has become irrational,' says Althea CEO Joshua Fegan. 'It's very saturated, with product from places like Canada, South Africa and Colombia'. He says most of the consumption is by way of dried flower, which implies folk might be smoking the devil's lettuce for jollies rather than using it medicinally. We'll delve further into Althea's new direction below. The dope on how to get it right While most suppliers have withered, a handful prosper via differentiated strategies and perhaps a bit of luck. They are producing meaningful revenues and – in some cases - profits. The Perth-based Little Green Pharma derives 80% of its revenue from the local market, but its greater fortunes align to the rapidly evolving European market. Germany is in the throes of partial legalisation. In France, the company supplies a pilot program that's a precursor to legalisation. Little Green's owns a production facility in Denmark – Europe's biggest – purchased from Canada's Canopy Growth for a knock-down $20 million three years ago. Two hours from the German border, the facility provides a streamlined route to the biggest Continental markets. 'It's very unlikely a site like this will be built again in the foreseeable future,' Little Green CEO Paul Long says. Meanwhile, the company's Busselton facility becomes a 'craft' producer of a small amount of slowly cured, hand trimmed, genetically superior stuff. Naturally, this attracts a better margin. In the year to March 2025 Little Green grew its revenue by 43%, to a record $36.8 million 'against a backdrop of significant regulatory change and intense competition'. European revenues doubled. Adjusted for non-cash items, Little Green managed underlying earnings of $2.9 million compared with a previous $1.6 million loss. From gummies to suppositories Bioxyne (ASX:BXN) has a modest $64 million market cap, but that's big enough to confer 'sector leader' status. Bioxyne's engine room is Breathe Life Sciences (BLS), acquired via scrip in 2023. BLS makes and distributes medical cannabis and other consumer health products, either under its own brands or third-party labels. (locally, Bioxyne is also the only licensed maker of MDMA and psilocybin for authorised prescribers and pyschedelic clinical trials). In 2019 the company launched in the UK and Japan via its well-known Dr Watson brand, covering everything from gummies, to vapes to suppositories. BLS too has entered the German market with a deal to supply a minimum 1.6 tonnes of cannabis flower and finished product to two clients. The company expects the agreement will reap a minimum of $5.6 million of revenue in the 2025-26 year. Ja, das ist gut! Bioxyne CEO Sam Watson expects German demand to rapidly overtake the $1 billion a year Australian market. On June 12 the company upgraded full-revenue expectations from $25 million to $28 million, a lofty step up from the previous year's $9.65 million. The Ebay of medicinal dope Formerly known as Cronos Australia, Vitura Health (ASX:VIT) doesn't produce any of its own material, but operates a marketplace that sells hundreds of flowers and oils from third party suppliers. Vitura also has expanded into prescription nicotine vapes. The company has built a network of physical and online prescribers, mainly via acquisition. Vitura owns the Canview marketplace, Doctors on Demand telehealth business, CDA Clinics (medical cannabis telehealth) and the clinic chain Candor Medical. In May, Vitura's 50% joint venture Flora acquired the digital platform Heyday Medical, 'one of Australia's most respected medicinal cannabis clinics'. Established in 2020, the chain claims to have serviced more than more than 5000 patients. Last November Flora acquired the Releaf Group, which operates telehealth and physical clinics. In a March quarter update, Vitura said full-year revenue was unlikely to meet the targeted 10% improvement. But the June quarter implies a yearly run rate of $138 million, up 11%. Management also expects a 20% improvement on last year's normalised underlying earnings of $8.4 million. Putting the pep into soft drinks Coming back to Althea, the company's new schtick is entering the North American market for THC-infused beverages. (THC is the psychoactive component of cannabis). Yep, these bevvies are legal in Canada and the US and are sold in bottle shops alongside alcohol. Althea's foray is by way of its subsidiary Peak. Althea's Fegan says when Peak started producing in 2021, only 4% of cannabis consumers had tried these drinks. Now, the number is more like one-quarter of them. He says the drinks have a similar effect to a similar sized serve of alcohol, but without the hangover. 'It ticks a lot of boxes as a good consumer product,' he says. Peak's competitive edge is its technique to produce the THC emulsion, without the 'planty' taste of dope. Peak's offerings include seltzers, sodas and mocktails – but it's not yet putting the 'pep' into Pepsi. Peak Canada has just launched its own brand Snap Back, a heady mix of THC and rosin (pine resin). By December Althea expects to have four or five US production sites, as close to distributors as possible. 'These big alcohol companies are looking closely at this space and our job is to develop drinks for those type of companies and produce them at scale," Fegan says. In the December half, Althea derived $8.2 million of revenue in Canada and the company expects this to grow during the summer months. Given the sale of its Australian business, Althea in May withdrew its full-year guidance of revenue between $26-33 million and underlying earnings of $800,000 to $1.1 million. Althea lost $2.6 million in the March quarter. But Fegan says the company should be cash flow positive without the drag of the divested Australian business.
Irish Daily Mirror
20-07-2025
- Irish Daily Mirror
Man appears before court charged in connection with €1.6m drugs haul in Wexford
A 46-year-old man charged in connection with a €1.6m drugs haul in County Wexford appeared before a special sitting of Gorey District Court Sunday afternoon. Fintan Fanning of Slaney Drive, Ballycarney, Enniscorthy, Co. Wexford, came before Judge Kevin Staunton. Fanning was charged with on July 18 at Tincurry, Ballycarney, Enniscorthy, Co. Wexford, he had in his possession a controlled drug, namely Cannabis, for the purpose of selling or supply to another in contravention of the Misuse of Drugs Regulations 2017 and 2019 under Section 5 of the Misuse of Drugs Act, 1972. Herbal cannabis worth an estimated €1.6m was seized at Tincurry, Ballycarney, on Friday last following a targeted joint operation involving An Garda Siochana and Revenue's Customs Service. In the course of a joint operation conducted by the Garda National Drugs and Organised Crime Bureau (GNDOCB) and Revenue Officers, a van was intercepted by Gardai in Ballycarney, Wexford, on Friday last, July 18. During the search of the van, approximately 80 kilos of herbal cannabis was discovered with an estimated street value of €1.6m (pending analysis). The accused was arrested at the scene and was detained for questioning under Section 2 of the Criminal Justice (Drug Trafficking) Act, 1996. The accused appeared in court wearing a grey tracksuit, with slight beard, and heavy tattooing around the neck area. He said close to his lawyer during the hearing which lasted less than ten minutes. Det. Garda Dean Healy told Judge Stauntion that on July 19 he arrested the accused and charged him as set out on the charge sheet. He arrested the accused at 15.56 and charged him at 16.03. When the charge was put to the acused he made 'no comment' said Det. Healy. Defence Counsel, Craig Phillips, B.L. instructed by Eoin O'Sullivan, Solicitor, said there would be no application for bail. He applied for free legal aid but no statement of means is yet available to the court, but would be provided at a later date. Sergt. Stephen Ennis told the court he would be seeking a remand in custody to appear before Wexford District Court on Tuesday next via video link. Judge Staunton said he would grant free legal aid subject to a statement of means being made available to the court. Judge Staunton remanded the accused, as requested, in custody to appear before Wexford District Court via video link on Tuesday night. Following the short hearing the accused was escorted from the court by two Gardaí. Subscribe to our newsletter for the latest news from the Irish Mirror direct to your inbox: Sign up here.
